This presentation contains “forward-looking statements” within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share repurchases, capital expenditures, acquisitions, benefits of investments and partnerships, business strategies, the potential impact of COVID-19 on our operations or financial results and other matters. Such statements can be identified by words such as: “expected,” “expects,” “expect,” “forecast,” “would,” “estimate,” “will,” or similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could make our actual results differ from expected results, please see our latest Annual Report on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise.

This presentation also contains non-GAAP financial information. Management uses this information in its internal analysis of results and believes this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For definitions of applicable non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non-GAAP Financial Measures included in the Company’s financial reports on Forms 10-Q and 10-K and related press releases.
BUSINESS OVERVIEW

PRESIDENT AND CEO
Chuck Kummeth

HEADQUARTERS
Minneapolis, MN

NUMBER OF EMPLOYEES
~2,300

WORLDWIDE PRESENCE
35 Locations

FY2020 REVENUES
$739M

NASDAQ
TECH

MARKET CAP
~$13B

82% CONSUMABLES

10% INSTRUMENTS

6% SERVICES

2% ROYALTIES

ANTIBODIES

PROTEINS

AUTOMATED PROTEIN ANALYSIS

IMMUNOASSAYS

TISSUE PATHOLOGY

CLINICAL CONTROLS

LIQUID BIOPSY
FY20 REVENUE BY CUSTOMER TYPE & GEOGRAPHY

$739M

22% OEM

17% DISTRIBUTORS

23% ACADEMIA

38% PHARMA/BIOTECH

18% ASIA

57% AMERICAS

25% EMEA
FOUR KEY STRATEGIES FOR SUSTAINED GROWTH

- GEOGRAPHIC EXPANSION
- CORE PRODUCT INNOVATION
- GAP FILLING M&A AND MARKET EXPANSION
- CULTURE CREATION AND TALENT
LAYING THE FOUNDATION FOR A SUSTAINABLE FUTURE

**ENVIRONMENTAL**
- Continual progress toward sustainability at largest global manufacturing site:
  - ISO 14001 Certification
  - Energy management
  - Water management:
    - Reduced wastewater by 4M gallons/year
  - Waste management:
    - Eliminated use of radioactive materials

**SOCIAL**
- Diverse and inclusive workplace:
  - 50% of global workforce are female
  - 52% of scientists are female
  - Over 30% of workforce are minorities
  - Employees encouraged to volunteer and do charitable work in their communities
  - Partner and sponsor of the Science Museum of Minnesota

**GOVERNANCE**
- Board membership includes:
  - Diverse membership
  - Deep scientific expertise and relevant life sciences business experience
  - Led by independent Chair
## OUR SEGMENT STRUCTURE

### PROTEIN SCIENCES

<table>
<thead>
<tr>
<th>REAGENT SOLUTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Develop and manufactures biological reagents used in all aspects of life science research</td>
</tr>
</tbody>
</table>

### ANALYTICAL SOLUTIONS

<table>
<thead>
<tr>
<th>R&amp;D SYSTEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manual and automated protein analysis solutions that improve the efficiency of process work streams &amp; quantitate secreted proteins</td>
</tr>
</tbody>
</table>

### DIAGNOSTICS & GENOMICS

<table>
<thead>
<tr>
<th>DIAGNOSTIC REAGENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Develops and manufactures controls, calibrators and diagnostic assays for the regulated diagnostic market</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GENOMICS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advanced, tissue morphology friendly RNA IN SITU hybridization (ISH) assay for transcriptome analysis &amp; prostate cancer molecular diagnostic</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>R&amp;D SYSTEMS</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLINICAL CONTROLS</td>
</tr>
<tr>
<td>proteinSimple</td>
</tr>
</tbody>
</table>

| ACD |
| exosomedx |
DIAGNOSTICS & GENOMICS

DIAGNOSTIC REAGENTS

TISSUE BIOPSY AND SPATIAL ANALYSIS

LIQUID BIOPSY TEST & DISCOVERY PLATFORM
**SEROLOGY/DIAGNOSTICS**

- Kantaro COVID-SeroKlir semi-quantitative antibody test kit
- 98.8% sensitivity/99.6% specificity
- Detects IgG antibodies against 2 viral epitopes
- EUA & CE mark
- ExoCOVID-19 RT-PCR for SARS-CoV-2 detection

**PROTEINS AND ANTIBODIES**

- Virus spike proteins (S1, S2 & RBD)
- Nucleocapsid proteins
- Antibodies to virus S1, S2 & N proteins
- Key reagents enabling other Covid-19 diagnostic assays

**MULTIPLEXING**

- Cytokine and pro-inflammatory biomarker immunoassays
- Data available in 75 minutes
- Provides insights into COVID-19 patient management

**RNAscope™ PROBES**

- Direct visualization of the virus and estimates of the viral load in any tissue
- Retain tissue morphological context
- RNAcope can be combined with IHC on the same slide for simultaneous RNA and protein detection
RESEARCH PRODUCTIVITY TOOLS

SIMPLE WESTERN

- Hands-free, fully automated western...no gels, no film, no manual analysis
- Protein identification and quantification
- 3 Hours from sample to answer vs. manual process that can take up to 2 days

BIOMARKER DISCOVERY WORKFLOW

- Transcriptomics:
  - Gene expression tools for tissue, exosomes and/or cfDNA
  - ACD, ExosomeDx
- Proteomics:
  - Protein expression as diagnostic signatures
  - Single/Multiplex immunoassays, automated multiplex (Ella)

TISSUE PATHOLOGY (ACD)

- Spatial analysis with single cell resolution
- Highly sensitive and specific
- Multiplexing capabilities
- Get the answer the first time with ACD probes
EXOSOME BASED LIQUID BIOPSY

COMPLETE PROFILING OF exoRNA

EXOSOME RELEASE
- Active process from living cells, part of intercellular communication
- Exosomes contain the entire RNA transcriptome from the donor cells, along with proteins, glycans & metabolites

BIOFLUID
- Multiple Biofluids
- From as little as 0.5 mL up to 2.0 mL

EXOSOME ISOLATION
1) Clinical grade (*Highly reproducible
2) RNAseq Whole Transcriptome Sequencing

BIOMARKER PATHWAY ANALYSIS
Exosome RNA analysis enables real-time longitudinal monitoring of cellular processes
1) Biofluid content
2) Pathway mapping

INDICATIONS TIMELINE:
2017
- PHARMA CDx: Biomarker Discovery, Clinical Trials, Companion Diagnostics, EGFR, BRAF, ARV7
- UROLOGY: EPI

2021
- TRANSPLANT REJECTION: Kidney
- EPI Repeat Biopsy and TERT

2023
- NEURODEGENERATIVE DISEASE: Alzheimer’s, Parkinson’s Disease
- EPI Active Surveillance
CELL & GENE THERAPY WORKFLOW SOLUTION

1. Leukapheresis
   White blood cells obtained from patient through leukapheresis

2. Cloudz™
   Antibody-coated beads used to activate the T cells

3. TcBuster™
   Activated T cells are reprogrammed to express Chimeric Antigen Receptors (CARs)

4. RNAscope™
   Reprogrammed T cells are screened for CAR gene expression

5. • GMP Proteins
   • ProDots™
   CARs expressing T cells are expanded ex vivo

6. • Immunocytochemistry
   • Flow Cytometry Antibodies
   Expanded T cells are tested for CAR expression

7. Simple Plex™ Assays
   Patient receives lymphodepleting chemotherapy prior to T cell treatment

8. Ella™
   CAR T cells are transferred back into the patient and Ella is used to monitor Cytokine Release Syndrome (CRS)
## END MARKET BREAKDOWN

<table>
<thead>
<tr>
<th>END MARKETS</th>
<th>MARKET SIZE</th>
<th>MARKET GROWTH RATE</th>
<th>BIO-TECHNE GROWTH RATE</th>
<th>BIO-TECHNE MARKET PENETRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PROTEOMIC RESEARCH REAGENTS</strong></td>
<td>$3B</td>
<td>MID-SINGLE DIGIT</td>
<td>8%-10%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>PROTEIN ANALYTICAL TOOLS</strong></td>
<td>$2B-$3B</td>
<td>MID-SINGLE DIGIT</td>
<td>15%-20%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>CELL CULTURE &amp; GENE THERAPY</strong></td>
<td>$3B-$5B</td>
<td>&gt;20%</td>
<td>∞</td>
<td>1%</td>
</tr>
<tr>
<td><strong>DIAGNOSTIC REAGENTS</strong></td>
<td>$1B-$2B</td>
<td>MID-SINGLE DIGIT</td>
<td>4%-6%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>TISSUE PATHOLOGY</strong></td>
<td>$1B-$2B</td>
<td>MID-SINGLE DIGIT</td>
<td>20%-30%</td>
<td>5%</td>
</tr>
<tr>
<td><strong>LIQUID BIOPSY</strong></td>
<td>$3B-$4B</td>
<td>&gt;20%</td>
<td>∞</td>
<td>1%</td>
</tr>
</tbody>
</table>
FINANCIAL RESULTS UNDER CURRENT LEADERSHIP

ORGANIC REVENUE GROWTH

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2013</td>
<td>$311M</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2014</td>
<td>0%</td>
<td>3%</td>
<td>4%</td>
<td>6%</td>
<td>6%</td>
<td>9%</td>
<td>10%</td>
<td>4%</td>
</tr>
<tr>
<td>FY 2015</td>
<td></td>
<td>4%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2016</td>
<td></td>
<td></td>
<td>6%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2017</td>
<td></td>
<td></td>
<td></td>
<td>6%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>9%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4%</td>
<td></td>
</tr>
</tbody>
</table>

ADJUSTED OPERATING INCOME ($M)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2013</td>
<td>169</td>
<td>184</td>
<td>190</td>
<td>198</td>
<td>208</td>
<td>239</td>
<td>244</td>
<td>246</td>
</tr>
<tr>
<td>FY 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CASH FROM OPERATIONS ($M)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2013</td>
<td>124</td>
<td>137</td>
<td>139</td>
<td>144</td>
<td>170</td>
<td>182</td>
<td>205</td>
<td></td>
</tr>
<tr>
<td>FY 2014</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2015</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2017</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2018</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2019</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FY 2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
POSITIONED FOR STRONG FINANCIAL PERFORMANCE

**REVENUE**

<table>
<thead>
<tr>
<th>FY14</th>
<th>FY17</th>
<th>FY20</th>
<th>FY25</th>
</tr>
</thead>
<tbody>
<tr>
<td>$358M</td>
<td>$563M</td>
<td>$739M</td>
<td>~$1.5B</td>
</tr>
</tbody>
</table>

**Rev CAGR**

- Analytical Solutions: +15–20%
- Reagent Solutions: +5–7%
- Protein Sciences: +8–11%
- Diagnostic Reagents: +4–6%
- Genomics — ACD & ExoDx: +20–30%
- Diagnostics & Genomics: ~+20%

**ADJ. OPERATING INCOME**

<table>
<thead>
<tr>
<th>FY14</th>
<th>FY17</th>
<th>FY20</th>
<th>FY25</th>
</tr>
</thead>
<tbody>
<tr>
<td>$180M</td>
<td>$208M</td>
<td>$246M</td>
<td>~$0.6B</td>
</tr>
</tbody>
</table>

**OM%**

- Analytical Solutions: ~30%
- Reagent Solutions: +50%
- Protein Sciences: Mid 40s%
- Diagnostics Reagents: ~30%
- Genomics — ACD & ExoDx: mid 30s%
- Diagnostics & Genomics: Low 30s%

* All figures are expressed in millions ($M) or billions ($B)
** Assumes no further unannounced acquisitions

© 2021 Bio-Techne®. All rights reserved.
THANK YOU